Best Peptide Stores

Compound research

MOTS-c: Research Overview & Current Status

By the Best Peptide Stores Editorial TeamLast reviewed 2026-08-08 · Also known as: Mitochondrial Open Reading Frame of the 12S rRNA-c
Preclinical research

MOTS-c is a Mitochondrial-derived peptide (MDP). Current research status: preclinical research. As of current search results, no completed or registered human clinical trials of MOTS-c or MOTS-c analogs were identified; the evidence base is exclusively cell-culture and animal-model research to date.

Overview

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene region rather than nuclear DNA, distinguishing it from most regulatory peptides. Under metabolic stress it translocates to the nucleus and influences expression of nuclear genes involved in metabolic homeostasis, and its mechanism is centrally linked to AMPK pathway activation.

Mitochondrial-derived peptide (MDP)

Research timeline

  1. 2015

    Early review discussed MOTS-c as a candidate 'longevity' mitochondrial-derived peptide, including association of an MOTS-c-region mtDNA polymorphism with longevity in a Northeast Asian population.

    Source →

  2. 2021

    Study reported MOTS-c improves glucose metabolism in skeletal muscle and increases with exercise in humans, positioning it as an exercise-responsive metabolic regulator.

    Source →

  3. 2021

    In vitro study on aged human placenta-derived mesenchymal stem cells reported MOTS-c improved mitochondrial homeostasis via AMPK activation and mTORC1 inhibition.

    Source →

  4. 2023

    Review article summarized MOTS-c's therapeutic potential across metabolic disease, inflammation, and aging models.

    Source →

  5. 2023

    Mouse study reported MOTS-c reduced neuropathic pain behavior via AMPK-mediated inhibition of microglial activation and oxidative damage after spared nerve injury.

    Source →

Active & recent research

In vitro, aged human placenta-derived MSCs

MOTS-c effects on mitochondrial homeostasis in aged mesenchymal stem cells

AMPK activation and mTORC1 inhibition as a mechanism for restoring youthful mitochondrial function

Source →
Mouse spared nerve injury model

MOTS-c in neuropathic pain

Reduction of microglial activation and spinal oxidative damage via AMPK pathway

Source →
Animal ischemic tissue flap model

MOTS-c and soft tissue/flap survival

Lysosomal membrane stabilization, angiogenesis, and collagen remodeling in transplanted tissue

Source →
Preclinical muscle bioenergetics study

MOTS-c and skeletal muscle bioenergetics

PGC-1a/AMPK-dependent improvement of intrinsic muscle mitochondrial efficiency

Source →

Key findings

  • A 2023 review in a peer-reviewed journal characterized MOTS-c as a 'promising' mitochondrial-derived peptide across metabolic, inflammatory, and aging research models, while noting its exploratory stage.
  • A 2021 study reported that exercise increases MOTS-c levels in human skeletal muscle and circulation, suggesting it functions as an exercise-responsive signaling peptide, though this reflects endogenous physiology rather than exogenous administration outcomes.
  • Animal and cell studies have consistently implicated AMPK activation and mTORC1 inhibition as the core mechanism behind MOTS-c's reported effects on glucose metabolism, inflammation, and cellular aging markers.
  • No human clinical trials of exogenously administered MOTS-c have been identified in current research; all reported benefits come from preclinical (cell culture and animal) models and should be interpreted accordingly.

Safety & regulatory notes

MOTS-c has no FDA approval and, per current research, has not entered registered human clinical trials as an administered therapeutic. There is no established human safety or pharmacokinetic profile for exogenous MOTS-c administration; all available data are preclinical.

How this site makes money

We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →

Where it's sold for research

We haven't built a dedicated vendor-availability page for MOTS-c yet. See our full research-peptide vendor rankings →

MOTS-c FAQ

Has MOTS-c been tested in humans?+

Endogenous MOTS-c levels have been measured in human blood and muscle (e.g., in exercise studies), but no completed clinical trials evaluating exogenously administered MOTS-c in humans have been identified in current research.

What is MOTS-c's proposed mechanism?+

Research models point to activation of AMPK and inhibition of mTORC1 signaling as the primary pathway through which MOTS-c is reported to influence metabolic and mitochondrial function in cell and animal studies.

Is MOTS-c approved for any medical use?+

No. MOTS-c has no FDA approval or approved medical indication anywhere; it remains an investigational research compound studied only in preclinical models.

What conditions has MOTS-c been studied in?+

Preclinical studies have explored MOTS-c in models of metabolic dysfunction, aging cell homeostasis, neuropathic pain, and tissue/flap survival, but all in animal or cell-culture settings, not human trials.

Sources for this page (7)

  1. 1 https://pubmed.ncbi.nlm.nih.gov/36761202/
  2. 2 https://pubmed.ncbi.nlm.nih.gov/33639272/
  3. 3 https://pubmed.ncbi.nlm.nih.gov/37285113/
  4. 4 https://pubmed.ncbi.nlm.nih.gov/42153537/
  5. 5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905433/
  6. 6 https://pubmed.ncbi.nlm.nih.gov/41520850/
  7. 7 https://pubmed.ncbi.nlm.nih.gov/26289118/

Related: all compound research overviews · research radar · full vendor rankings · methodology